Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer Patients

• Published in: Human Immunology 2006-03, Vol.67 (3), p.188-195
• Main Authors: Salih, Helmut Rainer, Goehlsdorf, Dennis, Steinle, Alexander
• Format: Article
• Language: English
• Subjects: cancer; Cell Line, Tumor; Cell Membrane - metabolism; Down-Regulation; Gastrointestinal Neoplasms - blood; Hematologic Neoplasms - blood; Histocompatibility Antigens Class I - blood; Histocompatibility Antigens Class I - metabolism; Humans; Killer Cells, Natural - metabolism; Matrix Metalloproteinase 1 - metabolism; metalloprotease; MICB; NK Cell Lectin-Like Receptor Subfamily K; NK cells; NKG2D; Receptors, Immunologic - biosynthesis; Receptors, Natural Killer Cell
• ISSN: 0198-8859; 1879-1166; 1365-2567
• DOI: 10.1016/j.humimm.2006.02.008

MICA, a ligand of the activating immunoreceptor NKG2D, is released by tumor cells in a soluble form and can be detected in sera of tumor patients at significant levels. Soluble MICA has been proposed to counteract NKG2D-mediated immunosurveillance of tumors. Here, we report that MICB, the second member of the human MIC protein family, is likewise shed by metalloproteases from tumor cells and is present in sera of patients with gastrointestinal tumors. While cell-bound MICB causes downregulation of surface NKG2D, soluble MICB did not alter NKG2D expression on NK cells in vitro. Thus, proteolytic shedding of MICB by tumor cells may impair immunogenicity of tumors primarily by reducing NKG2D-ligand densities on malignant cells.